Core Viewpoint - The Zhejiang Securities Regulatory Bureau has issued a decision regarding Minsheng Securities Co., Ltd. for violations during its continuous supervision of Zhejiang Weikang Pharmaceutical Co., Ltd.'s initial public offering process [1] Group 1: Violations Identified - Minsheng Securities failed to adequately monitor the abnormal delays in construction projects and did not perform sufficient verification procedures [1] - The conclusions drawn in the continuous supervision documents for Weikang Pharmaceutical in 2023 were not cautious enough, indicating deficiencies in internal controls within the investment banking operations [1] Group 2: Regulatory Actions - The actions of Minsheng Securities violated Article 5, Paragraph 1 of the "Administrative Measures for Sponsorship of Securities Issuance and Listing" (CSRC Order No. 170) [1] - The responsible representatives, Ren Shaozhong and Zhong Desong, are held primarily accountable for the violations [1] - The Zhejiang Securities Regulatory Bureau has decided to issue a warning letter as an administrative regulatory measure against Minsheng Securities [1]

Core Viewpoint - The A-share market is experiencing a surge in flu-related stocks, driven by rising flu activity in southern provinces and the emergence of the H3N2 strain, which has led to increased investor interest in pharmaceutical companies [1][2] Company Performance - **Jinshi Yiyao**: Increased by 13.44%, with a total market value of 4.644 billion [2] - **Guangji Pharmaceutical**: Rose by 9.97%, total market value of 2.448 billion [2] - **Te Yi Pharmaceutical**: Gained 8.78%, market value of 5.209 billion [2] - **Hualan Biological Engineering**: Up by 8.59%, with a market value of 12.9 billion [2] - **Lingkang Pharmaceutical**: Increased by 7.01%, market value of 4.291 billion [2] - **Hengdi Pharmaceutical**: Rose by 6.60%, market value of 5.466 billion [2] - **Innotec**: Increased by 5.37%, market value of 4.459 billion [2] - **Weikang Pharmaceutical**: Up by 4.76%, market value of 3.471 billion [2] - **Yirui Biological**: Increased by 4.67%, market value of 4.359 billion [2] Market Trends - The China CDC reported a slow increase in respiratory disease cases nationwide, with flu activity rising in southern provinces and remaining low in northern regions [1] - Experts suggest that the flu season may arrive earlier this year, with a potential increase in infection rates due to lower immunity against the H3N2 strain [1]

Market Overview - On October 17, the traditional Chinese medicine sector declined by 0.99%, with Tianmu Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3839.76, down 1.95%, while the Shenzhen Component Index closed at 12688.94, down 3.04% [1] Stock Performance - Notable gainers in the traditional Chinese medicine sector included: - Weikang Pharmaceutical: closed at 23.39, up 3.54% with a trading volume of 84,100 shares and a turnover of 26.66 million [1] - Enwei Pharmaceutical: closed at 31.40, up 2.45% with a trading volume of 24,700 shares and a turnover of 78.62 million [1] - Zhongsheng Pharmaceutical: closed at 17.45, up 2.11% with a trading volume of 706,300 shares and a turnover of 1.244 billion [1] - Major decliners included: - Tianmu Pharmaceutical: closed at 18.40, down 5.30% with a trading volume of 120,100 shares and a turnover of 22 million [2] - Jilin Aodong: closed at 20.23, down 3.39% with a trading volume of 226,500 shares and a turnover of 465 million [2] Capital Flow - The traditional Chinese medicine sector experienced a net outflow of 736 million from institutional investors, while retail investors saw a net inflow of 582 million [2][3] - Key stocks with significant capital flow included: - Zhongsheng Pharmaceutical: net inflow of 72.58 million from institutional investors, but a net outflow of 131 million from retail investors [3] - Tianmu Pharmaceutical: net inflow of 19.99 million from institutional investors, with net outflows from both retail and speculative investors [3]

Core Viewpoint - The innovative drug concept stocks continue to be active, with significant gains observed in several companies [2] Company Performance - Huabang Health reached the daily limit increase in stock price [2] - Other companies such as Shenlian Bio, Shutaishen, Chenxin Pharmaceutical, Weikang Pharmaceutical, and Hite Bio also experienced upward movement in their stock prices [2]

维康药业公开发行募集资金总额为83,134.74万元，扣除发行费用后，募集资金净额为72,559.56万 元。维康药业最终募集资金净额较原计划多18,554.56万元。维康药业于2020年8月19日披露的招股书显 示，公司拟募集资金54,005.00万元，分别用于医药大健康产业园一期项目（中药饮片及中药提取、研发 中心、仓储中心）、营销网络中心建设项目、补充营运资金项目。 | | 2024 年 | 2023 年 | | 本年比上年增 減 | 2022年 | | | --- | --- | --- | --- | --- | --- | --- | | | | 调整前 | 调整后 | 调整后 | 调整前 | 调整后 | | 营业收入 | 351.198.567.67 | 519,621,071.15 | 519.621.071.15 | -32.41% | 532.441.947.54 | 532.441.947.54 | | (元) | | | | | | | | 归属于上市公 司股东的净利 | -147.426.253.43 | -8,038,557.83 | -8.954.344.50 | -1.546. ...

Group 1 - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao for cash, which is expected to constitute a major asset restructuring [1] - Fosun Pharma's subsidiary plans to transfer 100% equity of Shanghai Cloning, with a transaction value of up to 1.256 billion yuan [1] Group 2 - *ST Songfa's subsidiary signed a shipbuilding contract worth approximately 400-600 million USD for four VLCCs, expected delivery between late 2026 and mid-2027 [3] - Qibin Group obtained financing support of up to 90 million yuan for share repurchase [4] Group 3 - Shapuaisi's shareholder plans to reduce holdings by up to 3% of the company's total shares [5] - *ST Kaixin intends to use up to 310 million yuan for cash management in safe and liquid financial products [6] Group 4 - Junchen Technology's shareholders plan to transfer 2.5% of the company's shares due to personal funding needs [7] - Jingliang Holdings received an administrative regulatory measure from Hainan Securities Regulatory Bureau for improper revenue recognition involving 299 million yuan [7] Group 5 - Tongcheng Holdings received a cash dividend of 24.6643 million yuan from Changsha Bank [9] - Shenyang Chemical appointed Chen Liguo as the new general manager [10] Group 6 - Huaguang Huaneng signed a contract for a 160 million yuan waste heat boiler project [15] - Shuxian Valley's subsidiary completed the re-registration of a health food product [16] Group 7 - Xuanta Pharmaceutical's new specification for a diabetes treatment drug was approved [17] - Panlong Pharmaceutical's application for a pain relief gel patch was accepted by the drug regulatory authority [18] Group 8 - Zhiguang Electric's subsidiary won a procurement contract worth 164 million yuan for a storage system [19] - Chitianhua's production facility resumed operations after maintenance [20] Group 9 - Haitong Development's application for a specific A-share issuance was accepted by the Shanghai Stock Exchange, aiming to raise 210 million yuan [20] - Risheng Technology's shareholders plan to transfer 4.02% of the company's shares [33] Group 10 - Pingmei Shares' controlling shareholder plans a strategic restructuring with Henan Energy Group [35] - Shenghui Integration's controlling shareholder committed not to reduce shareholdings for 12 months [37] Group 11 - Agricultural Bank and Bank of China will no longer establish supervisory boards, with their functions transferred to the audit committees [39][40] - Dongfang Yuhong's subsidiary signed a contract for a seawater pipeline project worth 2.524 billion USD [40][41] Group 12 - Ganfeng Lithium plans to introduce investors for a capital increase of up to 2.5 billion yuan [50] - Hanyu Pharmaceutical intends to raise up to 968 million yuan for various projects [51]

Market Overview - On September 26, the Traditional Chinese Medicine (TCM) sector declined by 0.38%, with Weikang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3828.11, down 0.65%, while the Shenzhen Component Index closed at 13209.0, down 1.76% [1] Stock Performance - Notable gainers in the TCM sector included: - *ST Changyao: Closed at 3.88, up 3.47% with a trading volume of 134,100 shares [1] - Fangsheng Pharmaceutical: Closed at 12.08, up 2.11% with a trading volume of 274,600 shares [1] - Huaren Sanjiu: Closed at 28.39, up 1.50% with a trading volume of 133,600 shares [1] - Major decliners included: - Weikang Pharmaceutical: Closed at 23.66, down 6.30% with a trading volume of 81,000 shares [2] - Zhendong Pharmaceutical: Closed at 6.57, down 4.09% with a trading volume of 518,000 shares [2] - Zhongsheng Pharmaceutical: Closed at 17.00, down 2.41% with a trading volume of 295,000 shares [2] Capital Flow - The TCM sector experienced a net outflow of 298 million yuan from institutional investors, while retail investors saw a net inflow of 396 million yuan [2] - Key stocks with significant capital flow included: - Huaren Sanjiu: Net inflow of 44.98 million yuan from institutional investors [3] - Fangsheng Pharmaceutical: Net inflow of 33.39 million yuan from institutional investors [3] - Dong'e Ejiao: Net inflow of 32.19 million yuan from institutional investors [3]

Group 1: Investment and Fundraising - Hanyu Pharmaceutical plans to raise no more than 968 million yuan for the development of semaglutide and other projects [1] - Ganfeng Lithium intends to introduce investors for a capital increase of up to 2.5 billion yuan [9] Group 2: Strategic Restructuring - Pingmei Shenma Holdings is undergoing a strategic restructuring as directed by the Henan provincial government, which will not affect the company's operations significantly [2][8] - Shennong Holdings is also involved in a strategic restructuring with no change in control or significant impact on operations [7][8] Group 3: Clinical Trials and Approvals - XinNuoWei's subsidiary received approval for clinical trials of a drug for treating mild Alzheimer's disease, marking a significant milestone in the development of biosimilar drugs [3] - Tainkang's subsidiary has received approval for clinical trials of CKBA cream for rosacea, a first-class innovative drug in China [4] - Baili Tianheng's drug, iza-bren, has been included in the list of breakthrough therapies, indicating its potential in treating advanced urinary tract cancer [5] Group 4: Contracts and Projects - Zhongyou Engineering signed an EPC contract worth 2.524 billion USD for a seawater pipeline project in Iraq, expected to positively impact future revenues [6]

Core Viewpoint - The launch of the phase III clinical trial for "Huangjia Soft Liver Granules" by Weikang Pharmaceutical is a significant step towards evaluating its efficacy and safety in treating chronic hepatitis B liver fibrosis, with the potential to enhance treatment options in this area [1][2][3] Group 1: Clinical Trial Details - The phase III clinical trial aims to assess the effectiveness and safety of "Huangjia Soft Liver Granules" for chronic hepatitis B liver fibrosis, involving 19 centers including Anhui Medical University First Affiliated Hospital [1] - The trial will include 480 participants and is designed as a randomized, double-blind, placebo-controlled, multi-center study [1] - Previous phase II trial results indicated that "Huangjia Soft Liver Granules" demonstrated good efficacy and safety, with clinical benefits for patients outweighing potential risks [1] Group 2: Market Context and Company Position - There are currently only four traditional Chinese medicines undergoing clinical trials for liver fibrosis, with "Huangjia Soft Liver Granules" being one of the few advancing to phase III, indicating a leading position in this therapeutic area [2] - Weikang Pharmaceutical has established a robust research and development framework, including multiple provincial-level research centers and collaborations with notable scientists, enhancing its competitive edge in the pharmaceutical industry [2] - The company has successfully developed the "Yinhuang Diyan" product, gaining significant market recognition, and is also exploring new product lines such as "Lingzhi Spore Powder" to create a second growth curve [2] Group 3: Future Outlook - The steady progress of the phase III clinical trial for "Huangjia Soft Liver Granules" is expected to lead to breakthroughs in liver disease treatment, potentially improving the clinical management of chronic hepatitis B in China [3]

Core Viewpoint - Weikang Pharmaceutical announced the initiation of a Phase III clinical trial to evaluate the efficacy and safety of Huangjia Soft Liver Granules in treating chronic hepatitis B virus-related liver fibrosis [1] Group 1: Company Information - Weikang Pharmaceutical is collaborating with Yingkerui (Zhuhai Jinwan) Pharmaceutical Co., Ltd. for the clinical trial [1] - The leading unit for the trial is Shanghai University of Traditional Chinese Medicine Affiliated Shuguang Hospital, along with 19 clinical trial centers including Anhui Medical University First Affiliated Hospital and Chongqing University Affiliated Three Gorges Hospital [1] Group 2: Clinical Trial Details - The clinical trial is designed as a randomized, double-blind, multi-center, placebo-controlled study [1] - The focus of the trial is on the effectiveness and safety of Huangjia Soft Liver Granules for patients with liver fibrosis characterized by liver qi deficiency and blood stasis [1]